LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

LENZNasdaqHealthcareBiotechnology
$7.44 -0.34 (-4.37%)

Company Overview

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Price Chart

Historical Trend (Absolute Values)
LENZ Price
05/1405/2206/01

Financial Metrics

Market Capitalization$219.79M
P/E Ratio
Earnings Per Share (EPS)-$4
Dividend Yield
Beta (Volatility)1.669
Price to Book (P/B)0.9464
52-Week Range$6.61 - $50.40

LAST SCRARED: June 1, 2026

Compare LENZ

Analyze valuation multiples and growth parameters side-by-side with other public equities.

Compare Stock Now
VersusHub

© 2026 VersusHub. All rights reserved.